Product Code: GVR-4-68039-991-9
Breast Cancer Liquid Biopsy Market Growth & Trends:
The global breast cancer liquid biopsy market size is expected to reach USD 1.7 billion by 2030, expandingat a CAGR of 22.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth.
With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment. There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.
A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.
Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in June 2022, NeoGenomics's subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.
Breast Cancer Liquid Biopsy Market Report Highlights:
- In 2021, the circulating tumor cells segment held a dominant revenue share owing to the effectiveness and precision offered by CTCs in the detection of cancer
- The early detection segment is projected to grow at the fastest CAGR over the forecast period, owing to the increasing adoption of liquid biopsy in early diagnosis of cancer and the rising need to provide effective treatment
- Treatment selection was the highest revenue-generating segment in 2021 owing to the availability of a high number of products that aid treatment selection
- Asia Pacific is expected to witness the fastest growth during the forecast period owing to increasing prevalence, improving healthcare infrastructure, and growing population
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation
- 1.1.1 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 Secondary Sources
- 1.3.3 Primary Research
- 1.3.4 Details Of Primary Research
- 1.4 Information Or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach 1: Commodity Flow Approach
- 1.6.1.2 Approach 2: Country - Wise Market Estimation Using Bottom - Up Approach
- 1.7 Global Market: Cagr Calculation
- 1.8 Research Assumptions
- 1.9 List Of Secondary Sources
- 1.10 List Of Primary Sources
- 1.11 Objectives
- 1.11.1 Objective 1:
- 1.11.2 Objective 2:
- 1.12 List of Abbreviations
Chapter 2 Executive Summary
Chapter 3 Breast Cancer Liquid Biopsy Market Variables, Trends, & Scope
- 3.1 Breast Cancer Liquid Biopsy Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Ancillary Market Outlook - In Vitro Diagnostics (Ivd) Market
- 3.2 Penetration And Growth Prospect Mapping
- 3.3 Market Dynamics
- 3.4 Market Driver Analysis
- 3.4.1 Increasing Prevalence Of Breast Cancer
- 3.4.2 Increasing Adoption Of Liquid Biopsies In Cancer Diagnosis
- 3.4.3 Need To Provide Early Diagnosis And Treatment
- 3.5 Market Restraint Analysis
- 3.5.1 High Cost Associated With Breast Cancer Liquid Biopsy Tests
- 3.5.2 Regulatory & Reimbursement Hurdles
- 3.6 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
- 3.7 Porter's Five Forces Analysis
Chapter 4 Breast Cancer Liquid Biopsy Market - Segment Analysis, By Circulating Biomarkers, 2018 - 2030 (USD Million)
- 4.1 Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Movement Analysis
- 4.1.1 Circulating Tumor Cells (Ctcs)
- 4.1.1.1 Circulating Tumor Cells (Ctcs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.1.2 Circulating Cell - Free Dna (Cfdna)
- 4.1.2.1 Circulating Cell - Free Dna (Cfdna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.1.3 Extracellular Vesicles (Evs)
- 4.1.3.1 Extracellular Vesicles (Evs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.1.4 Other Circulating Biomarkers
- 4.1.4.1 Other Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 5 Breast Cancer Liquid Biopsy Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)
- 5.1 Breast Cancer Liquid Biopsy Market: Application Movement Analysis
- 5.1.1 Early Detection/Screening
- 5.1.1.1 Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 5.1.2 Diagnosis
- 5.1.2.1 Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 5.1.3 Treatment Selection
- 5.1.3.1 Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 5.1.4 Monitoring
- 5.1.4.1 Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Breast Cancer Liquid Biopsy Market - Segment Analysis, by Region, 2018 - 2030 (USD Million)
- 6.1 Breast Cancer Liquid Biopsy Market: Regional Movement Analysis
- 6.2 North America
- 6.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.2.2 U.S.
- 6.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.2.3 Canada
- 6.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.3 Europe
- 6.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.3.2 U.K.
- 6.3.2.1 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.3.3 Germany
- 6.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.3.4 France
- 6.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.3.5 Italy
- 6.3.5.1 Italy Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.3.6 Spain
- 6.3.6.1 Spain Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.4 Asia Pacific
- 6.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.4.2 Japan
- 6.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.4.3 China
- 6.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.4.4 India
- 6.4.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.4.4 Australia
- 6.4.4.1 Australia Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.4.5 South Korea
- 6.4.5.1 South Korea Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.5 Latin America
- 6.5.1 Latin America Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.5.2 Brazil
- 6.5.2.1 Brazil Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.5.3 Mexico
- 6.5.3.1 Mexico Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.5.3 Argentina
- 6.5.4.1 Argentina Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.6 Mea
- 6.6.1 Mea Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.6.2 South Africa
- 6.6.2.1 South Africa Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.6.3 Saudi Arabia
- 6.6.3.1 Saudi Arabia Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
- 6.6.4 UAE
- 6.6.4.1 UAE Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
Chapter 7 Breast Cancer Liquid Biopsy Market: Competitive Analysis
- 7.1 Recent developments and impact analysis, by key market participants
- 7.1.1 Ansoff Matrix
- 7.1.2 Major Deals And Strategic Alliances Analysis
- 7.1.2.1 Market Expansion
- 7.1.2.2 Product Launch
- 7.1.2.3 Acquisition
- 7.1.2.4 Partnerships And Collaborations
- 7.2 Company Categorization
- 7.2.1 Innovators
- 7.2.2 Market Leaders
- 7.3 Vendor Landscape
- 7.3.1 List Of Key Distributors And Channel Partners
- 7.3.2 Key Customers
- 7.3.3 Key Company Market Share Analysis, 2021
- 7.4 Public Companies
- 7.4.1 Company Market Position Analysis
- 7.4.2 Heat Map Analysis
- 7.4.3 Regional Network Map
- 7.4.4 Competitive Dashboard Analysis
- 7.4.4.1 Market Differentiators
- 7.5 Private Companies
- 7.5.1 List Of Key Emerging Companies
- 7.5.2 Heat Map Analysis
- 7.5.3 Regional Network Map
Chapter 8 Company Profiles
- 8.1 The Menarini Group
- 8.1.1 Company Overview
- 8.1.2 Financial Performance
- 8.1.3 Product Benchmarking
- 8.1.4 Strategic Initiatives
- 8.2 NeoGenomics Laboratories
- 8.2.1 Company Overview
- 8.2.2 Financial Performance
- 8.2.3 Product Benchmarking
- 8.2.4 Strategic Initiatives
- 8.3 F. Hoffmann - La Roche Ltd.,
- 8.3.1 Company Overview
- 8.3.2 Financial Performance
- 8.3.2 Product Benchmarking
- 8.3.4 Strategic Initiatives
- 8.4 Myriad Genetics, Inc.
- 8.4.1 Company Overview
- 8.4.2 Financial Performance
- 8.4.3 Product Benchmarking
- 8.4.4 Strategic Initiatives
- 8.5 Thermo Fisher Scientific, Inc.
- 8.5.1 Company Overview
- 8.5.2 Financial Performance
- 8.5.3 Product Benchmarking
- 8.5.4 Strategic Initiatives
- 8.6 QIAGEN
- 8.6.1 Company Overview
- 8.6.2 Financial Performance
- 8.6.2 Product Benchmarking
- 8.6.4 Strategic Initiatives
- 8.7 Biocept, Inc.
- 8.7.1 Company Overview
- 8.7.2 Financial Performance
- 8.7.3 Product Benchmarking
- 8.7.4 Strategic Initiatives
- 8.8 Sysmex Corporation
- 8.8.1 Company Overview
- 8.8.2 Financial Performance
- 8.8.3 Product Benchmarking
- 8.9.4 Strategic Initiatives
- 8.9 Fluxion Biosciences, Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Performance
- 8.9.3 Product Benchmarking
- 8.9.4 Strategic Initiatives
- 8.10 Epic Sciences, Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Performance
- 8.9.3 Product Benchmarking
- 8.9.4 Strategic Initiatives